Suppr超能文献

在适合接受异基因造血细胞移植的个体中,采用减低强度预处理方案后进行allo-HSCT 会导致预后不良:一项加拿大单中心研究及与注册数据的比较。

Inferior outcomes with reduced intensity conditioning followed by allogeneic hematopoietic cell transplantation in fit individuals with acute lymphoblastic leukemia: a Canadian single-center study and a comparison to registry data.

机构信息

Hans Messner Allogeneic Transplant Program, Princess Margaret Hospital Cancer Centre, University Health Network, Toronto, Canada.

Department of Medicine, University of Toronto, Toronto, Canada.

出版信息

Leuk Lymphoma. 2021 Sep;62(9):2193-2201. doi: 10.1080/10428194.2021.1910688. Epub 2021 Apr 8.

Abstract

Allogeneic hematopoietic cell transplantation (HCT) can offer cure to some patients with acute lymphoblastic leukemia (ALL). It remains unclear how conditioning intensity affects transplant outcomes in ALL. In this retrospective study, we compared outcomes between 27 patients <60 who received reduced intensity conditioning (RIC) at Princess Margaret Hospital Cancer Center (PMCC) and 226 Cell Therapy Transplant Canada (CTTC) age-matched controls who received myeloablative conditioning (MAC) between 2007 and 2018. Compared to CTTC patients, PMCC patients had an inferior 2-y OS: 0.29 (95% CI: 0.11-0.49) vs 0.63 (0.56-0.70), HR = 2.10 (1.23-3.55),  0.006, higher TRM: 0.41 (0.22-0.60) vs 0.24 (0.18-0.30), HR = 2.00 (1.05-3.81),  0.04 and a trend toward increased risk of relapse: 0.36 (0.17-0.56) versus 0.17 (0.12-0.22), HR = 1.72 (0.82-3.62),  0.15. In multivariate analysis, RIC and the use of T-cell depletion (TCD) were associated with inferior OS. In ALL patients <60, the use of RIC with TCD is associated with inferior allogeneic HCT outcomes.

摘要

异基因造血细胞移植(HCT)可以为一些急性淋巴细胞白血病(ALL)患者提供治愈机会。目前尚不清楚预处理强度如何影响 ALL 患者的移植结果。在这项回顾性研究中,我们比较了 2007 年至 2018 年间在玛格丽特公主癌症中心(PMCC)接受低强度预处理(RIC)的 27 名<60 岁的患者和 226 名年龄匹配的接受清髓性预处理(MAC)的加拿大细胞治疗移植(CTTC)患者的结果。与 CTTC 患者相比,PMCC 患者的 2 年 OS 较差:0.29(95%CI:0.11-0.49)比 0.63(0.56-0.70),HR=2.10(1.23-3.55),P=0.006,TRM 更高:0.41(0.22-0.60)比 0.24(0.18-0.30),HR=2.00(1.05-3.81),P=0.04,且复发风险呈增加趋势:0.36(0.17-0.56)比 0.17(0.12-0.22),HR=1.72(0.82-3.62),P=0.15。多变量分析显示,RIC 和 T 细胞耗竭(TCD)的使用与 OS 较差相关。在<60 岁的 ALL 患者中,RIC 联合 TCD 的使用与异基因 HCT 结局较差相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验